Osimertinib vs Trastuzumab Deruxtecan
Osimertinib vs Trastuzumab Deruxtecan: Overview
This comparison examines the pharmacological differences between Osimertinib and Trastuzumab Deruxtecan.
Mechanism of Action
Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.
Pharmacokinetics
Half-life: Osimertinib β 48 hours.
Chemical Properties
Molecular Formula: Osimertinib β C28H33N7O2.
Molecular Weight: Osimertinib β 499.6050 g/mol.
Type: Osimertinib β Small molecule; Trastuzumab Deruxtecan β Antibody drug conjugate.